Foretinib (GSK 136089), the first multi-tyrosine kinase inhibitor targeting c-MET, was investigated clinically and found with a TTP of 4.2 months and median OS of 15.7 months in sorafenib-naïve HCC patients. The gene discussed is MET; the disease is hepatocellular carcinoma.